The findings arrive after a swirl of regulatory uncertainty surrounding the trivalent (three-strain) vaccine, mRNA-1010.

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

Combriax demonstrates strong immunogenicity across age groups, exceeding comparator vaccines for multiple influenza strains ...

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

Randomized trial shows superiority in adults 50 and older ...

Relative vaccine efficacy was 26.6 percent, which met the criteria for noninferiority, superiority, higher-level superiority.

Immune-priming events such as COVID-19 and influenza vaccinations may have cross-protective effects on the incidence of other viral ARIs.

Increasing influenza vaccination coverage to 70% could prevent more than 30,000 pediatric hospitalizations and 123 pediatric ...

Moderna Inc MRNA shares are trading higher Friday morning as traders react to peer reviewed Phase 3 flu-vaccine data. Here’s ...

Flu vaccination rates among adults show early signs of stabilizing after several years of decline, though pediatric rates remain historically low, preliminary CDC data shows. The CDC’s Weekly ...